Isoform-Specific Antibodies for SP-R210 Receptor Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current compositions and methods lack specificity in targeting distinct isoforms of the surfactant protein A receptor SP-R210, particularly SP-R210 L and SP-R210 S, which are crucial for modulating immune responses and inflammation in conditions such as influenza pneumonia.
Innovation Solution
Development of monoclonal antibodies and antigen binding fragments that specifically bind to either the SP-R210 L or SP-R210 S isoforms, allowing for targeted modulation of immune responses and inflammation, including the use of recombinantly produced antibodies and fragments for pharmaceutical preparations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional compositions and methods are used, then general immune modulation is achieved, but specificity in targeting distinct SP-R210 isoforms is lacking
Solution Approach 1:
The patent segments the SP-R210 receptor into two distinct isoforms (SP-R210 L and SP-R210 S) and develops specific binding partners for each isoform. This segmentation allows selective targeting of each isoform's unique functional characteristics, enabling precise modulation of immune responses without cross-reactivity between isoforms.
Solution Approach 2:
The patent applies local quality by creating binding partners with isoform-specific binding properties. Each binding partner is designed to recognize and bind only to its corresponding SP-R210 isoform, providing localized and specific immune modulation at the molecular level rather than general non-specific binding.
2Reliability
If isoform-specific binding partners are developed, then selective modulation of immune responses is achieved, but manufacturing complexity increases
Solution Approach 1:
The patent uses recombinant DNA technology as an intermediary method to produce isoform-specific binding partners. By encoding the binding partners with specific amino acid sequences that confer isoform selectivity, the manufacturing process achieves reliable selective modulation while maintaining scalability through standard recombinant protein production techniques.
3Reliability
If SP-R210 L-mediated signaling is disrupted, then protection against influenza is enhanced, but potential effects on other SP-R210 isoform functions may occur
Solution Approach 1:
The patent applies inversion by developing binding partners that bind to and stabilize the active conformation of SP-R210 L, thereby enhancing its protective signaling functions. This inverted approach ensures that disrupting pathogenic signaling while preserving or enhancing protective isoform functions, achieving selective modulation rather than broad suppression.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The specific binding partners effectively inhibit the binding of pathogenic microorganisms to macrophages, modulate inflammatory pathways, and enhance T-cell mediated immunity, providing protection against influenza and potentially other infections by disrupting SP-R210 L-mediated signaling.
Implementation Method 1
monoclonal antibodies and antigen binding fragments that specifically bind to either the SP-R210 L or SP-R210 S isoforms
Data Source
Figure 1
Figure 2
Figure 3A~3B
AI summary
Provided are compositions and methods for use in prophylaxis, therapy and diagnosis of conditions which involve surfactant protein receptors (SPR) including the SPR for surfactant proteins A (SPA). Specific binding partners, including monoclonal antibodies, for the SP-R210L and SP-R210S isoforms, and methods of using such binding partners are included. Fragments of the monoclonal antibodies, and fusion proteins that contain them are also included. Also provided are methods for prophylaxis and/or therapy for an individual in need thereof by administering to the individual an effective amount of monoclonal antibody or antigen binding fragment thereof. The monoclonal antibodies are bind with specificity to epitopes in one or both of the SP-R210OL and SP-R210S isoforms.